

RECEIVED #8

MAR 15 2002


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

Applicant: Robert J. Peach, et al. **Examiner:** Not Yet Known
Serial No.: 09/865,321 **Group Art Unit:** 1646
Filed: May 23, 2001 **Docket No.:** 30436.57USU1
Title: SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on March 6, 2002.


By: Tracy TruickSUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

This Information Disclosure Statement is being filed herewith as a supplement to Applicant's June 19, 2001, Information Disclosure Statement which was submitted under 37 C.F.R. §1.97 (b)(1) within three months of the filing date of the national application (i.e. before August 23, 2001) on the merits. In accordance with 37 C.F.R. §1.98(d), copies of Exhibits 65-113 as set forth in the Form 1449 are included herewith.

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner. They are as follows:

- Linsley, et al., 1991, *J.Exp.Med.* "CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7" 174:561-569. **(Exhibit 65)**
- Gimmi, et al., 1993, *Proc.Natl.Acad.Sci. USA* "Human T-Cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation" 90:6586-6590. **(Exhibit 66)**
- Azuma et al., 1993 *Nature* "B70 antigen is a second ligand for CTLA-4 and CD28" 366:76-79. **(Exhibit 67)**
- Ronchese et al., 1994 *J.Exp.Med* "Mice Transgenic for a Soluble Form of Murine CTLA-4 Show Enhanced Expansion of Antigen-specific CD4 T Cells and Defective Antibody production In Vivo" 179:809-817. **(Exhibit 68)**
- Griggs et al., 1996 *J.Exp.Med* "The Relative Contribution of the CD28 and gp39 Costimulatory pathways in the Clonal Expansion and Pathgenic Acquisition of Self-reactive T Cells" 183:801-810. **(Exhibit 69)**
- Linsley et al., *J.Exp.Med* "CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7" 174:561-569. **(Exhibit 70)**
- Verwilghen et al., 1994 *J-Immunol.* Expression of Functional B& and CTLA4 on Rheumatoid Synovial T Cells" 153:1378-1385. **(Exhibit 71)**

- Blazar et al., 1994 *Blood* "In Vivo Blockade of CD28/CTLA4: Interaction With CTLA4-Ig Reduces Lethal Murine Graft-Versus-Host Disease Across the Major Histocompatibility Complex Barrier in Mice" 83:3815-3825. **(Exhibit 72)**
- Finck et al., *Science* "Treatment of Murine lupus with CTLA4Ig" 265:1225-1227. **(Exhibit 73)**
- Perrin et al., 1995 *J-Immunol* "Role of B7:CD28/CTLA4 in the Induction of Chronic Relapsing Experimental Allergic Encephalomyelitis" 154:1481-1490. **(Exhibit 74)**
- Pearson et al., 1994 *Transplantation* "Transplantation Tolerance Induced By CTLA4-Ig" 57:1701-1706. **(Exhibit 75)**
- Baliga et al., 1994 *Transplantation* "CTLA4Ig PROLONGS ALLOGRAFT SURVIVAL WHILE SUPPRESSING CELL-MEDIATED IMMUNITY" 58:1082-1090. **(Exhibit 76)**
- Tepper et al., 1994 *Transplantation Proceedings* "Tolerance Induction by soluble CTLA4 in a Mouse Skin Transplant Model" 26:3151-3154. **(Exhibit 77)**
- Perico et al., 1995 *Kidney International* "Toward novel antirejection strategies: In vivo immunosuppressive properties of CTLA4Ig" 47:241-246. **(Exhibit 78)**
- Finck et al., 1994 *Arthritis and Rheumatism* "Effects of CTLA4Ig in murine lupus" 37:S222. **(Exhibit 79)**
- Nishikawa et al., 1994 *Eur J. Immunol.* "Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis" 24:1249-1254. **(Exhibit 80)**
- Wallace et al., 1994 *Transplantation* "CTLA4ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers" 58:602-610. **(Exhibit 81)**

- Damle et al., *J. Immunol.* "Costimulation of T Lymphocytes with integrin Ligands intercellular Adhesion Molecule-1 or Vascular Cell Adhesion Molecule-1 Induces Functional Expression of CTLA-4, a Second Receptor for B7" 152:2686-2697. **(Exhibit 82)**
- Milich, et al., 1994 *J. Immunol* "Soluble CTLA-4 can suppress autoantibody production and elicit long term unresponsiveness in a novel transgenic model," 153:429-435. **(Exhibit 83)**
- Webb, et al., 1996 *Eur J. Immunol* "Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2," 26:2320-2328. **(Exhibit 84)**
- Van Oosterhout, et al., 1997 *Am.J.Respir. Cell Mol.Biol.* "Murine CTLA4-IgG Treatment Inhibits Airway Eosinophilia and Hyperresponsiveness and Attenuates IgE Upregulation in a Murine Model of allergic Asthma," 17:386-392. **(Exhibit 85)**
- Abams et al., 1999 *J-Clin-Invest* "CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. 103:1243-1252. **(Exhibit 86)**
- Ibrahim, et al., 1996 *Blood* "CTLA4Ig Inhibits Alloantibody Responses to Repeated Blood Transfusions," 88:4594-4600. **(Exhibit 87)**
- Lenschow, et al., 1995 *J Exp Med* "Differential Effects of anti-B7-1 and Anti-b&-2 Monoclonal Antibody Treatment on the Development of Diabetes in the Nonobese Diabetic Mouse," 181:1145-1155. **(Exhibit 88)**
- Lenschow, et al., 1992 *Science* "Long-Term Survival of Xenogeneic Pancreatic islet Grafts Induced by CTLA4Ig," 257:789-792. **(Exhibit 89)**

- Blazar, et al., 1994 *Blood* "In Vivo Blockade of CD28/CTLA4:B7/BB1 Interaction with CTLA4-Ig Reduces Lethal Murine Graft-Versus-Host Disease Across the Major Histocompatibility Complex Barrier in Mice," 83:3815-3825. **(Exhibit 90)**
- Griggs, et al., 1996 *J Exp Med* "The relative Contribution of the CD28 and gp39 Costimulatory pathways in the Clonal Expansion and Pathogenic Acquisition of Self-reactive T Cells," 183:801-810. **(Exhibit 91)**
- Sayegh., 1999 *J Clin Invest* "Finally, CTLA4Ig graduates to the clinic," 103:1223-1225. **(Exhibit 92)**
- Abrams, et al., 1999 *J Clin Invest* "CTLA4Ig-mediated blockade of T-cell costimulation I patients with psoriasis vulgaris," 103:1243-1252. **(Exhibit 93)**
- Wolfe, 1995 *Bailliere's Clinical Rheumatology* "The epidemiology of drug treatment failure in rheumatoid arthritis," 9:619-632. **(Exhibit 94)**
- Hochberg, et al., 1990 *Epidemiologic Reviews* "Epidemiology of Rheumatoid Arthritis: Update," 12:247-252. **(Exhibit 95)**
- Spector, 1990 *Epidemiology of Rheumatic Disease* "Rheumatoid Arthritis," 16:513-537. **(Exhibit 96)**
- Liu MF, Kohsaka H Sakurai H, Azuma m Okumura K Saito I, Miyasaka N, 1996 *Arthritis-Rheum* "The presence of costimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid arthritis synovium". Jan; 39(1): 110-4. **(Exhibit 97)**

- Sfrikakis PP, Via CS. 1997 *Clin-Immunol-Immunopathol* "Expression of CD28, CTLA4, CD80, CD86 molecules in-patients with autoimmune rheumatic diseases: implications for immunotherapy". Jun; 83(3): 195-8. **(Exhibit 98)**
- Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA, 1995. *J. Exp. Med.* "CD28-B7 blockade after all antigenic challenge in vivo inhibits Th1 cytokines but spares Th2". 181: 1869-1874. **(Exhibit 99)**
- Racusen LC; et. al. 1999 *Kidney-Int.* "The Baniff 97 working classification of renal allograft pathology".. 55(2): 713- 723. **(Exhibit 100)**
- Parkin D, Jacoby A, McNamee P, 2000 *J Neurol Neurosurg Psychiatry* "Treatment of multiple sclerosis with interferon β : an appraisal of cost-effectiveness and quality of life"; 68: 144-149. **(Exhibit 101)**
- Nortvedt MW, Riise T, Myhr KM, and Nyland HI, 1999 *Neurology*. "Quality of life in multiple sclerosis: measuring the disease effects more broadly"; 53(5): 1098-1103 **(Exhibit 102)**
- Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP, 1994 *Transplantation*. "Transplantation tolerance induced by CTLA4-Ig. 57:1701-1706. **(Exhibit 103)**
- Liao HX, Haynes BF, 1995 *Rheum-Dis-Clin-Noth-Am.* "Role of adhesion molecules in the pathogenesis of rheumatoid arthritis". Aug; 21(3): 715-40. **(Exhibit 104)**
- WO 95/33770, December 14, 1995, **(Exhibit 105)**
- Thomas R, Quinn C. 1996 *J-Immunol.* "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium". Apr 15; 156(8): 3074-86. **(Exhibit 106)**

- Verhoeven-AC; Boers-M; Tugwell-P, 1998. "Combination therapy in rheumatoid arthritis: updated systematic review" *Br-J-Rheumatol.* Jun;37 (6): 612-619 (**Exhibit 107**)
- Schiff M, 1997 *Am-J-Med.* "Emerging treatments for rheumatoid arthritis". Jan 27; 102 (1A): 11S-15S (**Exhibit 108**)
- Balsa A, Dixey J, Sansom DM, Maddison PJ, Hall ND, 1996 *Br-J-Rheumato.* "Differential expression of the costimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid synovial tissue" *l.* Jan; 35(1): 33-7 (**Exhibit 109**)
- Ranheim Ea, Kipps Tj, 1994 *Arthritis-Rheum.* "Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis" Nov;37 (11): 1637-1647 (**Exhibit 110**)
- Freeman GJ, Gribben JG, Boussiotis VA, et. al. 1993 *Science.* "Cloning of B7-2: a CTLA-4 counter receptor that costimulates human T cell proliferation" 262: 909-911. (**Exhibit 111**)
- Baliga P, Chavin KD, Qin L, et. al. *Transplantation* "CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity" 58(10): 1082-1090. (**Exhibit 112**)
- Thomas R, Quinn C, 1996 *J-Immuno* "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium" *l.* Apr 15;156(8): 3074-86 (**Exhibit 113**)

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that the references have been thoroughly reviewed or that any relevance of any portion of a reference is intended.

Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. § 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

No fee is deemed necessary in connection with the filing of this Supplemental Information Disclosure Statement. However, if any additional fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-0306.

Respectfully submitted,

Sarah B. Adriano

Sarah B. Adriano
Registration No. 34,470
Attorney for Applicants
Mandel & Adriano
35 No. Arroyo Parkway, Suite 60
Pasadena, California 91103
(626) 395-7801
Customer No. 26,941



FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number 30436.57USU1	Application Number 09/865,321
	Applicant Robert J. Peach et al.	
	Filing Date May 23, 2001	Group Art Unit 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLAS S	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLAS S	TRANSLATION	
						YES	NO
	WO 95/33770 (Exhibit 105)	December 14, 1995	PCT				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Linsley, et al., 1991, <i>J.Exp.Med.</i> "CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7" 174:561-569. (Exhibit 65)
	Gimmi, et al., 1993, <i>Proc.Natl.Acad.Sci. USA</i> "Human T-Cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation" 90:6586-6590. (Exhibit 66)
	Azuma et al., 1993 <i>Nature</i> "B70 antigen is a second ligand for CTLA-4 and CD28" 366:76-79. (Exhibit 67)
	Ronchese et al., 1994 <i>J.Exp.Med</i> "Mice Transgenic for a Soluble Form of Murine CTLA-4 Show Enhanced Expansion of Antigen-specific CD4 T Cells and Defective Antibody production In Vivo" 179:809-817. (Exhibit 68)
	Griggs et al., 1996 <i>J.Exp.Med</i> "The Relative Contribution of the CD28 and gp39 Costimulatory pathways in the Clonal Expansion and Pathgenic Acquisition of Self-reactive T Cells" 183:801-810. (Exhibit 69)
	Linsley et al., <i>J.Exp.Med</i> "CTLA-4 Is a Second Receptor for the B Cell Activation Antigen B7" 174:561-569. (Exhibit 70)
	Verwilghen et al., 1994 <i>J-Immunol.</i> Expression of Functional B& and CTLA4 on Rheumatoid Synovial T Cells" 153:1378-1385. (Exhibit 71)
	Blazar et al., 1994 <i>Blood</i> "In Vivo Blockade of CD28/CTLA4: Interaction With CTLA4-Ig Reduces Lethal Murine Graft-Versus-Host Disease Across the Major Histocompatibility Complex Barrier in Mice" 83:3815-3825. (Exhibit 72)
	Finck et al., <i>Science</i> "Treatment of Murine lupus with CTLA4Ig" 265:1225-1227. (Exhibit 73)
	Perrin et al., 1995 <i>J-Immunol</i> "Role of B7:CD28/CTLA4 in the Induction of Chronic Relapsing Experimental Allergic Encephalomyelitis" 154:1481-1490. (Exhibit 74)
	Pearson et al., 1994 <i>Transplantation</i> "Transplantation Tolerance Induced By CTLA4-Ig" 57:1701-1706. (Exhibit 75)
	Baliga et al., 1994 <i>Transplantation</i> "CTLA4Ig PROLONGS ALLOGRAFT SURVIVAL WHILE SUPPRESSING CELL-MEDIATED IMMUNITY" 58:1082-1090. (Exhibit 76)
	Tepper et al., 1994 <i>Transplantation Proceedings</i> "Tolerance Induction by soluble CTLA4 in a Mouse Skin Transplant Model" 26:3151-3154. (Exhibit 77)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449*

Docket Number

Application Number

30436.57USU1

09/865,321

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

Applicant

Robert J. Peach et al.

Filing Date

May 23, 2001

Group Art Unit

1646

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

- | | |
|--|---|
| | Perico et al., 1995 <i>Kidney International</i> "Toward novel antirejection strategies: In vivo immunosuppressive properties of CTLA4Ig" 47:241-246. (Exhibit 78) |
| | Finck et al., 1994 <i>Arthritis and Rheumatism</i> "Effects of CTLA4Ig in murine lupus" 37:S222. (Exhibit 79) |
| | Nishikawa et al., 1994 <i>Eur J. Immunol.</i> "Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis" 24:1249-1254. (Exhibit 80) |
| | Wallace et al., 1994 <i>Transplantation</i> "CTLA4Ig treatment ameliorates the lethality of murine graft-versus-host disease across major histocompatibility complex barriers" 58:602-610. (Exhibit 81) |
| | Damle et al., <i>J. Immunol.</i> "Costimulation of T Lymphocytes with integrin Ligands intercellular Adhesion Molecule-1 or Vascular Cell Adhesion Molecule-1 Induces Functional Expression of CTLA-4, a Second Receptor for B7" 152:2686-2697. (Exhibit 82) |
| | Milich, et al., 1994 <i>J. Immunol</i> "Soluble CTLA-4 can suppress autoantibody production and elicit long term unresponsiveness in a novel transgenic model," 153:429-435. (Exhibit 83) |
| | Webb, et al., 1996 <i>Eur J. Immunol</i> "Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2," 26:2320-2328. (Exhibit 84) |
| | Van Oosterhout, et al., 1997 <i>Am.J.Respir. Cell Mol.Biol.</i> "Murine CTLA4-IgG Treatment Inhibits Airway Eosinophilia and Hyperresponsiveness and Attenuates IgE Upregulation in a Murine Model of allergic Asthma," 17:386-392. (Exhibit 85) |
| | Abams et al., 1999 <i>J-Clin-Invest</i> "CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. 103:1243-1252. (Exhibit 86) |
| | Ibrahim, et al., 1996 <i>Blood</i> "CTLA4Ig Inhibits Alloantibody Responses to Repeated Blood Transfusions," 88:4594-4600. (Exhibit 87) |
| | Lenschow, et al., 1995 <i>J Exp Med</i> "Differential Effects of anti-B7-1 and Anti-b&-2 Monoclonal Antibody Treatment on the Development of Diabetes in the Nonobese Diabetic Mouse," 181:1145-1155. (Exhibit 88) |
| | Lenschow, et al., 1992 <i>Science</i> "Long-Term Survival of Xenogeneic Pancreatic islet Grafts Induced by CTLA4Ig," 257:789-792. (Exhibit 89) |
| | Blazar, et al., 1994 <i>Blood</i> "In Vivo Blockade of CD28/CTLA4:B7/BB1 Interaction with CTLA4-Ig Reduces Lethal Murine Graft-Versus-Host Disease Across the Major Histocompatibility Complex Barrier in Mice," 83:3815-3825. (Exhibit 90) |
| | Griggs, et al., 1996 <i>J Exp Med</i> "The relative Contribution of the CD28 and gp39 Costimulatory pathways in the Clonal Expansion and Pathogenic Acquisition of Self-reactive T Cells," 183:801-810. (Exhibit 91) |
| | Sayegh., 1999 <i>J Clin Invest</i> "Finally, CTLA4Ig graduates to the clinic," 103:1223-1225. (Exhibit 92) |
| | Abrams, et al., 1999 <i>J Clin Invest</i> "CTLA4Ig-mediated blockade of T-cell costimulation I patients with psoriasis vulgaris," 103:1243-1252. (Exhibit 93) |
| | Wolfe, 1995 <i>Bailliere's Clinical Rheumatology</i> "The epidemiology of drug treatment failure in rheumatoid arthritis," 9:619-632. (Exhibit 94) |
| | Hochberg, et al., 1990 <i>Epidemiologic Reviews</i> "Epidemiology of Rheumatoid Arthritis: Update," 12:247-252. (Exhibit 95) |

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

FORM 1449*

Docket Number

Application Number

30436.57USU1

09/865,321

Applicant

Robert J. Peach et al.

Filing Date

May 23, 2001

Group Art Unit

1646

**INFORMATION DISCLOSURE STATEMENT
IN AN APPLICATION**

(Use several sheets if necessary)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)


- Spector, 1990 *Epidemiology of Rheumatic Disease* "Rheumatoid Arthritis," 16:513-537. **(Exhibit 96)**
- Liu MF, Kohsaka H Sakurai H, Azuma m Okumura K Saito I, Miyasaka N, 1996. "The presence of costimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid arthritis synovium" *Arthritis-Rheum.* Jan; 39(1): 110-4. **(Exhibit 97)**
- Sfikakis PP, Via CS. 1997 "Expression of CD28, CTLA4, CD80, CD86 molecules in-patients with autoimmune rheumatic diseases: implications for immunotherapy". *Clin-Immunol-Immunopathol.* Jun; 83(3): 195-8. **(Exhibit 98)**
- Sayegh MH, Akalin E, Hancock WW, Russell ME, Carpenter CB, Linsley PS, Turka LA, 1995. *J. Exp. Med.* "CD28-B7 blockade after all antigenic challenge in vivo inhibits Th1 cytokines but spares Th2". 181: 1869-1874. **(Exhibit 99)**
- Racusen LC; et. al. 1999. "The Baniff 97 working classification of renal allograft pathology". *Kidney-Int.* 55(2): 713- 723. **(Exhibit 100)**
- Parkin D, Jacoby A, McNamme P, 2000. "Treatment of multiple sclerosis with interferon β : an appraisal of cost-effectiveness and quality of life" *J Neurol Neurosurg Psychiatry*; 68: 144-149. **(Exhibit 101)**
- Nortvedt MW, Riise T, Myhr KM, and Nyland HI, 1999. "Quality of life in multiple sclerosis: measuring the disease effects more broadly" *Neurology*; 53(5): 1098-1103 **(Exhibit 102)**
- Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP, 1994. "Transplantation tolerance induced by CTLA4-Ig. *Transplantation*, 57:1701-1706. **(Exhibit 103)**
- Liao HX, Haynes BF, 1995. "Role of adhesion molecules in the pathogenesis of rheumatoid arthritis" *Rheum-Dis-Clin-Noth-Am.* Aug; 21(3): 715-40. **(Exhibit 104)**
- Thomas R, Quinn C. 1996. "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium" *J-Immunol.* Apr 15; 156(8): 3074-86. **(Exhibit 106)**
- Verhoeven-AC; Boers-M; Tugwell-P, 1998. "Combination therapy in rheumatoid arthritis: updated systematic review" *Br-J-Rheumatol.* Jun;37 (6): 612-619 **(Exhibit 107)**
- Schiff M, 1997. "Emerging treatments for rheumatoid arthritis" *Am-J-Med.* Jan 27; 102 (1A): 11S-15S **(Exhibit 108)**
- Balsa A, Dixey J, Sansom DM, Maddison PJ, Hall ND, 1996. "Differential expression of the costimulatory molecules B7.1 (CD80) and B7.2 (CD86) in rheumatoid synovial tissue" *Br-J-Rheumatol.* Jan; 35(1): 33-7 **(Exhibit 109)**
- Ranheim Ea, Kipps Tj, 1994. "Elevated expression of CD80 (B7/BB1) and other accessory molecules on synovial fluid mononuclear cell subsets in rheumatoid arthritis" *Arthritis-Rheum.* Nov;37 (11): 1637-1647 **(Exhibit 110)**
- Freeman GJ, Gribben JG, Boussiotis VA, et. al. 1993. "Cloning of B7-2: a CTLA-4 counter receptor that costimulates human T cell proliferation" *Science*, 262: 909-911. **(Exhibit 111)**
- Baliga P, Chavin KD, Qin L, et. al. "CTLA4Ig prolongs allograft survival while suppressing cell-mediated immunity" *Transplantation*, 58(10): 1082-1090. **(Exhibit 112)**
- Thomas R, Quinn C, 1996 "Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium" *J-Immunol.* Apr 15;156(8): 3074-86 **(Exhibit 113)**

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.

*Substitute Disclosure Statement Form (PTO-1449) Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE



0300 #8 1646

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Applicant: Robert J. Peach, et al.

Serial No.: 09/865,321

MAR 12 2002

Filed: May 23, 2001

Docket: 30436.57USU1

TECH CENTER 1600/2900

Title: SOLUBLE CTLA4 MUTANT MOLECULES AND USES THEREOF

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this paper or fee is being deposited with the United States Postal as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on March 6, 2002.

By: 

Name: Tracy Trick

35 N. Arroyo Parkway, Suite 60
Pasadena, California 91103
March 6, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.8.
- ☒ Supplemental Information Disclosure Statement (37 C.F.R. §1.97(b)(3))
- ☒ Form 1449 (Information Disclosure Statement)
- ☒ Exhibits 65 - 113
- ☒ Return postcard

Please charge any additional fees or credit overpayment to Deposit Account No. 50-0306. A duplicate of this sheet is enclosed.

MANDEL & ADRIANO

35 No. Arroyo Parkway, Suite 60
Pasadena, California 91103
(626) 395-7801

By: 

Name: Sarah B. Adriano

Reg. No.: 34,470

Initials: SBA

Customer No. 26,941